-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
rac-Tenofovir-[d6]
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1020719-94-1.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 1020719-94-1 |
| Description | One isotopotic labelled form of Tenofovir, which is an analogue of acyclic phosphonate nucleotide and could be used in antiviral treatment as an everse transcriptase inhibitor. |
Product Information
| Synonyms | 2(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]-d6-phosphonic Acid;9-(2-Phosphonomethoxypropyl)adenine-d6; PMPA-d6; rac-GS-1278-d6; rac-Tenefovir-d6 |
| IUPAC Name | [1-(6-aminopurin-9-yl)-1,1,2,3,3,3-hexadeuteriopropan-2-yl]oxymethylphosphonic acid |
| Molecular Weight | 293.25 |
| Molecular Formula | C9H8D6N5O4P |
| Canonical SMILES | CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O |
| InChI | InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/i1D3,2D2,6D |
| InChIKey | SGOIRFVFHAKUTI-CUYPRXAISA-N |
| Melting Point | >250 °C (dec.) |
| Purity | 96.5% HPLC; 99% atom D |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | White to Off-White Solid |
| Storage | Store at -20°C |
| Complexity | 354 |
| Exact Mass | 293.11600142 |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs. |
| PSA | 146.19000 |
| Target | Reverse Transcriptase; HIV; HBV |
| XLogP3-AA | -1.6 |
